secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K/A
Filed at:   2026-07-16T21:20:16+00:00
Accession:  0001193125-26-306251
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics discloses separation agreement with former executive Craig Tooman
--------------------------------------------------------------------------------

- Salary continuation of $655,000 for 12 months plus lump sum cash severance of $250,000.
- Bonus payment of $283,746.03 and healthcare premium reimbursement of $46,896.48.
- Extended option exercise period: 24 months for 2023 Plan options, 12 months for 2018 Plan options.
- Acceleration of unvested options upon change of control within 12 months post-separation.
- Confidentiality, non-disparagement, non-solicitation covenants and release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/0001193125-26-306251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526306251/sln-20260710.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-306251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer